Chapter 28 : Clinical Significance, Diagnosis, and Treatment of Picornavirus Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Clinical Significance, Diagnosis, and Treatment of Picornavirus Infections, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817916/9781555812102_Chap28-1.gif /docserver/preview/fulltext/10.1128/9781555817916/9781555812102_Chap28-2.gif


The picornaviruses are a diverse group of human viral pathogens that together comprise the most common causes of infections of humans in the developed world. Within the picornavirus family are three well-known groups of human pathogens—the human rhinoviruses (HRVs), the enteroviruses (EVs) (including polioviruses, coxsackieviruses, and echoviruses), and the hepatoviruses (including hepatitis A). This chapter focuses on the rhinoviruses and enteroviruses. The HRVs include more than 100 serotypes in two main groups based on their cellular receptors. The major risk factor for HRV infection appears to be contact with young children. The majority of symptomatic EV infections in the United States are characterized by minor EV illnesses associated with fever and constitutional symptoms, with or without rashes. These illnesses are of clinical significance because they may mimic other diseases including bacterial sepsis, other viral exanthematous diseases, and herpes simplex infections. A recent review of EV-associated respiratory illnesses found that 46% of cases presented with upper respiratory infections, 13% with respiratory distress/apnea, 13% with pneumonia, 12% with otitis media, and fewer cases with bronchiolitis, wheezing, croup, and pharyngotonsillitis. New developments in the rapid diagnosis and therapy of these infections promise to significantly reduce the disease burden and the associated costs to affected individuals and to society.

Citation: Rotbart H. 2002. Clinical Significance, Diagnosis, and Treatment of Picornavirus Infections, p 357-365. In Semler B, Wimmer E (ed), Molecular Biology of Picornavirus. ASM Press, Washington, DC. doi: 10.1128/9781555817916.ch28

Key Concept Ranking

Viral Upper Respiratory Tract Infections
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Abdel-Rahman, S. M.,, and G. L. Kearns. 1999. Single oral dose escalation pharmacokinetics of pleconaril capsules in adults. J. Clin. Pharmacol. 39:613618.
2. Abzug, M. J.,, H. L. Keyserling,, M. L. Lee,, M. J. Levin,, and H. A. Rotbart. 1995. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin. Infect. Dis. 20:12011206.
3. Abzug, M. J.,, M. J. Levin,, and H. A. Rotbart. 1993. Profile of enterovirus disease in the first two weeks of life. Pediavr. Infect. Dis. J. 12:820824.
4. Al-Nakib, W.,, P. G. Higgins,, G. I. Barrow,, D. A. J. Tyrrell,, K. Andries,, G. V. Bussche,, N. Taylor,, and P. A. J. Janssen. 1989. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob. Agents Chemother. 33:522525.
5. Arola, M.,, O. Ruuskanen,, T. Ziegler,, J. Mertsola,, K. Nanto-Salonen,, A. Putto-Laurila,, M. K. Viljanen,, and P. Halonen. 1990. Clinical role of respiratory virus infection in acute otitis media. Pediatrics 86:848855.
6. Arruda, E.,, and F. G. Hayden,. 1995. Clinical studies of antiviral agents for picornaviral infections. In D. J. Jeffries, and E. DeCierrq (ed.), Antiviral Chemotherapy. John Wiley & Sons Ltd., New York, N.Y.
7. Arruda, E.,, A. Pitkaranta,, T. J. Witek, Jr.,, C. A. Doyle,, and F. G. Hayden. 1997. Frequency and natural history of rhinovirus infections in adults during autumn. J. Clin. Microbiol. 35:28642868.
8. Barrow, G. I.,, P. G. Higgins,, D. A. J. Tyrrell,, and K. Andries. An appraisal of the efficacy of the antiviral R 61837 in rhinovirus infections in human volunteers. Antivir. Chem. Chemother. 5:278283.
9. Berkowitz, R. B.,, and D. G. Tinkelman. 1987. Evaluation of oral terfenadine for treatment of the common cold. Am. Rev. Resp. Dis. 136:556560.
10. Buchman, C. A.,, W. J. Doyle,, D. Skoner,, P. Fireman,, and J. M. Gwaltney. 1994. Otologic manifestations of experimental rhinovirus infection. Laryngoscope 104:12951299.
11. Buontempo, P.,, S. Cox,, J. Wright-Minogue,, J. L. DeMartino,, A. Skelton,, E. Ferrari,, R. Albin,, E. J. Rozhon,, V. Girijavallabhan,, J. F. Modlin,, and J. F. O'Connell. 1997. SCH 48973: a potent, broad spectrum antienterovirus compound. Antimicrob. Agents Chemother. 41:12201225.
12. Capobianchi, M. R.,, D. Matteucci,, A. Glovannetti,, E. Soldaini,, M. Bendinei,, J. G. Stanton,, and F. Dianzani. 1991. Role of interferon in lethality and lymphoid atrophy induced by coxsackievirus S3 infection in mice. Virol. Immunol. 5:103110.
13.Centers for Disease Control and Prevention. 1996. Progress toward global eradication of poliomyelitis. Morb. Mortal. Wkly. Rep. 45:565568.
14.Centers for Disease Control and Prevention. 1997. Progress toward poliomyelitis eradication—-Africa, 1996. Morb. Mortal. Wkly. Rep. 46:321325.
15. Cherry, J. D., 1998. Enteroviruses: coxsackieviruses, echo-viruses, and polioviruses, p. 17871838. In R. D. Feigin, and J. D. Cherry (ed.), Textbook of Pediatric Infectious Diseases, 4th ed. W. B. Saunders, Philadelphia, Pa.
16. Chidekel, A. S.,, A. R. Bazzy,, and C. L. Rosen. 1994. Rhinovirus infection associated with severe lower respiratory tract illness and worsening lung disease in infants with bronchopulmonary dysplasia. Pediatr. Pulm. 18:261263.
17. Chonmaitree, T.,, and L. Mann,. 1995. Respiratory infections, p. 255270. In H. A. Rotbart (ed.), Human Enterovirus Infections. ASM Press, Washington, D.C.
18. Collinson, J.,, K. G. Nicholson,, E. Cancio,, J. Ashman,, D. C. Ireland,, V. Hammersley,, J. Kent,, and C. O'Callaghan. 1996. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 51:11151122.
19. Cox, S.,, P. Buontempo,, J. Wright-Minogue,, J. L. DeMartino,, A. M. Skelton,, E. Ferrari,, J. Schwartz,, E. J. Rozhon,, C. C. Linn,, V. Girijavallabhan,, and J. F. O'Connell. 1996. Antipicornavirus activity of SCH 47802 and analogues: in vitro and in vivo studies. Antivir. Res. 32:7179.
20. Douglas, R. M.,, B. W. Moore,, H. B. Miles,, L. M. Davies,, N. Graham,, P. Ryan,, D. Worswick,, and J. Albricht. 1986. Prophylactic efficacy of intranasal alpha A2-interferon against rhinovirus infections in the family setting. N. Engl. J. Med. 314:6570.
21. Elkhatieb, A.,, G. Hipskind,, D. Woerner,, and F. G. Hayden. 1993. Middle ear abnormalities during natural rhinovirus colds in adults. J. Infect. Dis. 168:618621.
22. Fox, M. P.,, M. A. McKinlay,, G. D. Diana,, and F. J. Dutko. 1991. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14- Antimicrob. Agents Chemother. 35:10401047.
23. Gadomski, A. M. 1993. Potential interventions for preventing pneumonia among young children: lack of effect of antibiotic treatment for upper respiratory infections. Pediatr. Infect. Dis.J. 12:115120.
24. Geniteau-Legendre, M.,, F. Forestier,, A. M. Quero,, and A. German. 1987. Role of interferon, antibodies and macrophages in the protective effect of Corynebacterium parvum on encephalomyocarditis virus-induced disease in mice. Antivir. Res. 7:161167.
25. Gilbert, L. L.,, A. Dakhama,, B. M. Bone,, E. E. Thomas,, and R. G. Hegele. 1996. Diagnosis of viral respiratory tract infections in children by using reverse transcription-PCR panel. J. Clin. Microb. 34:140143.
26. Gonzales, R.,, J. F. Steiner,, and M. A. Sande. 1998. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 278:901904.
27. Greenberg, S. B.,, M. W. Harmon,, R. B. Couch,, P. E. Johnson,, S. Z. Wilson,, C. C. Dacso,, K. Bloom,, and J. Quarles. 1982. Prophylactic effect of low doses of human leukocyte interferon against infection with rhinovirus. J. Infect. Dis. 145:542546.
28. Grimm, W.,, and H.-H. Muller. 1999. A randomized controlled trial of the effect of fluid extract of Echinacea Purpurea on the incidence and severity of colds and respiratory infections. Am. J. Med. 106:138143.
29. Gustafson, L. M.,, D. Proud,, O. Hendley,, F. G. Hayden,, and J. M. Gwaltney. 1996. Oral prednisone therapy in experimental rhinovirus infections. J. Allergy Clin. Immunol. 97:10091114.
30. Gwaltney, J. M., Jr. 1992. Combined antiviral and anti-mediator treatment of rhinovirus colds. J. Infect. Dis. 166: 776782.
31. Gwaltney, J. M., Jr., 1989. Rhinoviruses, p. 593. In A. S. Evans (ed.), Viral Infection of Humans. Plenum Press, New York, N.Y.
32. Gwaltney, J. M., Jr.,, J. Park,, R. A. Paul,, D. A. Edelman,, R. R. O'Connor,, and R. B. Turner. 1996. Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds. Clin. Infect. Dis. 22:656662.
33. Gwaltney, J. M., Jr.,, C. D. Phillips,, R. D. Miller,, and D. K. Riker. 1994. Computed tomographic study of the common cold. N. Engl. J. Med. 330:2530.
34. Gwaltney, J. M., Jr.,, and R. R. Rueckert,. 1997. Rhinovirus, p. 10251047. In D. D. Richman,, R. J. Whitley,, and F. G. Hayden (ed.). Clinical Virology. Churchill Livingstone, New York, N.Y.
35. Hayden, F. G.,, L. Diamond,, P. B. Wood,, D. C. Korts,, and M. T. Wecker. 1996. Effectiveness and safety of intranasal ipratropium bromide in common colds. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125:8997.
36. Hayden, E.,, J. K. Albrecht,, D. L. Kaiser,, and J. M. Gwaltney. 1986. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N. Engl. J. Med. 314:7175.
37. Hayden, E.,, and J. M. Gwaltney. 1983. Intranasal interferon alpha2 for prevention of rhinovirus infection and illness. J. Infect. Dis. 148:543550.
38. Hayden, E.,, and J. M. Gwaltney. 1984. Intranasal interferon-a2 treatment of experimental rhinovirus colds. J. Infect. Dis. 150:174180.
39. Hayden, F. G.,, A. Andries,, and P. A. J. Janssen. 1992. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 36:727732.
40. Heikkinen, T.,, M. Thint,, and T. Chonmaitree. 1999. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N. Engl. J. Med. 340:260264.
41. Hemila, H. 1994- Does vitamin C alleviate the symptoms of the common cold: a review of current evidence. Scand. J. Infect. Dis. 26:16.
42. Ho, M.,, E.-R. Chen,, K.-H. Hsu,, S. J. Twu,, K. T. Chen,, S. E Tsai,, J. R. Wang,, and S. R. Shih. 1999. An epidemic of enterovirus 71 infection in Taiwan. N. Engl. J. Med. 341:929935.
43. Jackson, J. L.,, C. Peterson,, and E. Lesho. 1997. A metaanalysis of zinc salts lozenges and the common cold. Arch. Intern. Med. 157:23732376.
44.. Jenista, J. A.,, K. R. Powell,, and M. A. Menegus. 1984. Epidemiology of neonatal enterovirus infection. J. Pediatr. 104:685690.
45. Johnston, S. L.,, P. K. Pattemore,, G. Sanderson,, S. Smith,, M. J. Campbell,, L. K. Josephs,, A. Cunningham,, B. S. Robinson,, S. H. Myint,, M. E. Ward,, D. A. Tyrrell,, and S. T. Holgate. 1996. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am. J. Respir. Crit. Care Med. 154: 654660.
46. Johnston, S. L.,, P. K. Pattemore,, G. Sanderson,, S. Smith,, F. Lampe,, and L. Josephs. 1995. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310:12251229.
47. Kaiser, L.,, D. Lew,, B. Hirschel,, R. Auckenthaler,, A. Morabia,, A. Heald,, P. Benedict,, F. Terrier,, W. Wunderli,, L. Matter,, D. Germann,, J. Voegeli,, and H. Stalder. 1996. Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions. Lancet 347:15071510.
48. Kandolf, R.,, A. Canu,, and P. H. Hofschneider. 1985. Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. J. Mol. Cell. Cardiol. 17:167181.
49. Kantor, E. S.,, and G. D. Hsiung. 1962. Pleurodynia associated with echo virus type 8. N. Engl. J. Med. 266: 661663.
50. Kaplan, M. H.,, S. W. Klein,, J. McPhee,, and R. G. Harper. 1983. Group B coxsackievirus infections in infants younger than three months of age: a serious childhood illness. Rev. Infect. Dis. 5:10191032.
51. Kearns, G. L.,, S. M. Abdel-Rahman,, L. P. James,, D. L. Blowey,, J. D. Marshall,, T. G. Wells,, R. F. Jacobs, and Pediatric Pharmacology Research Unit Network. 1999. Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Antimicrob. Agents Chemother. 43:634638.
52. Kishimoto, C.,, C. S. Crumpacker,, and W. H. Abelmann. 1988. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D. Cardiovasc. Res. 22:732738.
53. Langford, M. P.,, J. C. Barber,, V. E. Sklar,, S. W. Clark III,, P. A. Patriarca,, I. M. Onarato,, M. Yin-Murphy,, and G. J. Stanton. 1985. Vims-specific, early appearing neutralizing activity and interferon production in patients with acute hemorrhagic conjunctivitis. Curr. Eye Res. 4: 233239.
54. Langford, M. P.,, R. M. Kadi,, J. P. Ganley,, and M. Yin-Murphy. 1988. Inhibition of epidemic isolates of coxsackie virus type A24 by recombinant and natural interferon alpha and interferon beta. Inter-virology 29:320327.
55. Lopez-Guerrero, J. A.,, F. X. Pimentel-Muinos,, M. Fresno,, and M. A. Alonso. 1990. Role of soluble cytokines on the restricted replication of poliovirus in the monocylic U937 cell line. Virus Res. 16:225230.
56. Luks, D.,, and M. R. Anderson. 1996. Antihistamines and the common cold. A review and critique of the literature. J. Gen. Intern. Med. 11:240244.
57. Macknin, M. L.,, M. Piedmonte,, C. Calendine,, J. Janosky,, and E. Wald. 1998. Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial. JAMA 279:19992000.
58. Makela, M. J.,, T. Puhakka,, O. Ruuskanen,, M. Leinonen,, P. Saikku,, M. Kimpimaki,, S. Blomqvist,, T. Hyypiä,, and P. Arstila. 1998. Viruses and bacteria in the etiology of the common cold. J. Clin. Microbiol. 36:539542.
59. Marshall, S. 1998. Zinc gluconate and the common cold. Review of randomized controlled trials. Can. Fam. Phys. 44:10371042.
60. Martino, T. A.,, P. Liu,, M. Petric,, and M. J. Sole,. 1995. Enteroviral myocarditis and dilated cardiomyopathy: a review of clinical and experimental studies, p. 291351. In H. A. Rotbart (ed.), Human Enterovirus Infections. ASM Press, Washington, D.C.
61. McKinlay, M. A.,, J. A. Frank,, and B. A. Steinberg. 1986. Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice. J. Infect. Dis. 154: 676681.
62. McKinlay, M. A.,, and B. A. Steinberg. 1986. Oral efficacy of WIN 51711 in mice infected with human polio-virus. Antimicrob. Agents Chemother. 29:3032.
63. McKinney, R. E., Jr.,, S. L. Katz,, and G. M. Wilfert. 1987. Chronic enteroviral meningoencephalitis in agam-maglobulinemic patients. Rev. Infect. Dis. 9:334356.
64. Merigan, T.,, S. Reed,, T. Hall,, and D. Tyrrell. 1973. Inhibition of respiratory virus infection by locally applied interferon. Lancet i:536567.
65. Modlin, J. F. 1986. Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries. Rev. Infect. Dis. 8: 918926.
66. Modlin, J. E.,, R. Dagan,, L. E. Berlin,, D. M. Virshup,, R. H. Yolken,, and M. Menegus. 1991. Focal encephalitis with enterovirus infections. Pediatrics 88:841845.
67. Monto, A. S.,, S. A. Schwartz,, and J. K. Albrecht. 1989. Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families. Antimicrob. Agents Chemother. 33:387390.
68. Nicholson, K. G.,, J. Kent,, V. Hammersley,, and E. Gancio. 1996. Risk factors for lower respiratory complications of rhinovirus infections in elderly people living in the community: prospective cohort study. BMJ 313:11191123.
69. Nicholson, K. G.,, J. Kent,, and D. C. Ireland. 1993. Respiratory viruses and exacerbations of asthma in adults. BMJ 307:982986.
70. Nyquist, A.-C.,, R. Gonzales,, J. F. Steiner,, and M. A. Sande. 1998. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 279:875877.
71. Okada, I.,, A. Matsumori,, Y. Matoba,, M. Tominaga,, T. Yamada,, and C. Kowai. 1992. Combination treatment with ribavirin and interferon for coxsackievirus B3 replication. J. Lab. Clin. Med. 120:569573.
72. Otto, M. J.,, M. P. Fox,, M. J. Fancher,, M. F. Huhrt,, G. D. Diana,, and M. A. McKinlay. 1985. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 27:883886.
73. Parrott, R. H.,, S. Ross,, F. G. Burke,, and E. C. Rice. 1951. Herpangina: clinical studies of a specific infectious disease. N. Engl. J. Med. 245:275280.
74. Patel, J. A.,, B. Reisner,, N. Vizirinia,, M. Owen,, T. Chonmaitree,, and V. Howie. 1995. Bacteriological failure of amoxicillin-clavulanate in treatment of acute otitis media caused by nontypeable Haemophilus influenzae. J. Pediatr. 126:799806.
75. Pevear, D. C.,, T. M. Tull,, M. E. Seipel,, and J. M. Groarke. 1999. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43:21092115.
76. Pitkaranta, A.,, E. Arruda,, H. Malmberg,, and F. G. Hayden. 1997. Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. J. Clin. Microbiol. 35:17911793.
77. Pitkaranta, A.,, A. Virolainen,, J. Jero,, E. Arruda,, and F. G. Hayden. 1998. Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics 102:291295.
78. Rombaut, B.,, R. Vrijsen,, and A. Boeye. 1985. Comparison of arildone and 3-methylquercetin as stabilizers of poliovirus. Antivir. Res. Suppl. 1:6773.
79. Rotbart, H. A.,, A. Ahmed,, S. Hickey,, R. Dagan,, G. H. McCracken, Jr.,, R. J. Whitley,, J. F. Modlin,, M. Cascino,, J. F. O'Connell,, M. A. Menegus,, and D. Blum. 1997. Diagnosis of enterovirus infection by polymerase chain reaction of multiple specimen types. Pediatr. Infect. Dis. J. 16:409411.
80. Rotbart, H. A.,, P. J. Brennan,, K. H. Fife,, J. R. Romero,, J. A. Griffin,, M. A. Mckinlay,, and F. G. Hayden. 1998. Enterovirus meningitis in adults. Clin. Infect. Dis. 27: 896898.
81. Rotbart, H. A.,, J. F. O'Connell,, and M. A. McKinlay. 1998. Treatment of human enterovirus infections. Antivir. Res. 38:114.
82. Rotbart, H. A., 1995. Enteroviruses, p. 10041011. In P. R. Murray,, E. J. Baron,, M. A. Pfaller,, F. C. Tenover,, and R. H. Yolken (ed.), Manual of Clinical Microbiology, 6th ed. ASM Press, Washington, D.C.
83. Rotbart, H. A., 1997. Viral meningitis and the aseptic meningitis syndrome, p. 2346. In W. M. Scheld,, R. J. Whitley,, and D. T. Durack (ed.), Infections of the Central Nervous System, 2nd ed. Lippincott-Raven, Philadelphia, Pa.
84. Samo, T. C.,, S. B. Greenberg,, R. B. Couch,, J. Quarles,, P. E. Johnson,, S. Hook,, and M. W. Harmon. 1983. Efficacy and tolerance of intranasal applied recombinant leukocyte A interferon in normal volunteers. J. Infect. Dis. 148:535542.
85. Sasaki, O.,, T. Karaki,, and J. Imanishi. 1986. Protective effect of interferon on infections with hand, foot and mouth disease virus in newborn mice. J. Infect. Dis. 153: 498502.
86. Schiff, G. M.,, J. R. Sherwood,, E. C. Young,, and L. J. Mason. 1992. Prophylactic efficacy of WIN 54954 in prevention of experimental human coxsackievirus A21 infection and illness. Antivir. Res. 17(Suppl.):92.
87. Schmidt, H. J.,, and R. J. Fink. 1991. Rhinovirus as a lower respiratory pathogen in infants. Pediatr. Infect. Dis. J. 10:700702.
88. Sperber, S. J.,, J. O. Hendley,, F. G. Hayden,, D. K. Riker,, J. V. Sorrentino,, and J. M. Gwaltney, Jr. 1992. Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial. Ann. Intern. Med. 117:3741.
89. Strikas, R. A.,, L. J. Anderson,, and R. A. Parker. 1986. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970-1983. J. Infect. Dis. 153:346351.
90. Turner, R. B. 1998. The common cold. Pediatr. Ann. 27: 790795.
91. Turner, R. B.,, F. J. Dutko,, N. H. Goldstein,, G. Lockwood,, and F. G. Hayden. 1993. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob. Agents Chemother. 37:297300.
92. Turner, R. B.,, S. J. Sperber,, J. V. Sorrentino,, R. R. O'Connor,, J. Rogers,, A. R. Batouli,, and J. M. Gwaltney, Jr. 1997. Effectiveness of clemastine fumarate for treatment of rhinorrhea and sneezing associated with the common cold. Clin. Infect. Dis. 25:824830.
93. Turner, R. B.,, M. T. Wecker,, G. Pohl,, T. J. Witek,, E. McNally,, R. St. George,, B. Winther,, and F. G. Hayden. 1999. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1 for experimental rhinovirus infection: a randomized clinical trial. JAMA 281:17971804.
94. Wadia, N. H.,, P. N. Wadia,, S. M. Katrak,, and V. P. Misra. 1983. A study of the neurological disorder associated with acute hemorrhagic conjunctivitis due to enterovirus 70. J. Neurol. Neurosurg. Psych. 46:599610.
95. Webster, A. D. B.,, H. A. Rotbart,, T. Warner,, P. Rudge,, and N. Hyman. 1993. Diagnosis of enterovirus brain disease in hypogammaglobulinemic patients by polymerase chain reaction. Clin. Infect. Dis. 17:657661.
96. Whitley, R. J.,, C. G. Cobbs,, C. A. Alford, Jr.,, S. J. Soong,, M. S. Hirsch,, J. D. Connor,, L. Corey,, D. F. Han-ley,, M. Levin,, and D. A. Powell. 1989. Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. JAMA 262:234239.
97. Woods, M. G.,, G. D. Diana,, M. C. Rogge,, M. J. Otto,, F. J. Dutko,, and M. A. McKinlay. 1989. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 33:20692074.
98. Zhang, A.,, R. G. Nanni,, G. F. Arnold,, D. A. Oren,, T. Li,, A. Jacobo-Molkina,, R. L. William,, G. Kamer,, D. A. Rubenstein,, Y. Li,, E. Rozhon,, S. Cox,, P. Buontempo,, J. O'Connell,, J. Schwartz,, G. Miller,, C. Nash,, B. Bauer,, R. Versace,, A. Ganguly,, V. Girijavallabhan,, and E. Arnold. 1991. Structure of a complex of human rhinovirus 14 with a water soluble antiviral compound SCH 38057. J. Mol. Biol. 230:857867.
99. Zhang, A.,, R. G. Nanni,, D. A. Oren,, E. J. Rozhon,, and E. Arnold. 1992. Three-dimensional structure-activity relationships for antiviral agents that interact with picornavirus capsids. Semin. Virol. 3:453471.


Generic image for table

Clinical illnesses caused by picornavirus infections

Citation: Rotbart H. 2002. Clinical Significance, Diagnosis, and Treatment of Picornavirus Infections, p 357-365. In Semler B, Wimmer E (ed), Molecular Biology of Picornavirus. ASM Press, Washington, DC. doi: 10.1128/9781555817916.ch28

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error